Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q14749
UPID:
GNMT_HUMAN
Alternative names:
-
Alternative UPACC:
Q14749; Q5T8W2; Q9NNZ1; Q9NS24
Background:
Glycine N-methyltransferase (GNMT) plays a pivotal role in methyl group metabolism, catalyzing the methylation of glycine to form sarcosine. This process is crucial for regulating the balance between S-adenosyl-L-methionine and S-adenosyl-L-homocysteine, impacting various metabolic pathways.
Therapeutic significance:
GNMT deficiency is linked to mild hepatomegaly and chronic elevation of serum transaminases, highlighting its importance in liver health. Understanding GNMT's role could unveil new therapeutic strategies for managing liver diseases and metabolic disorders.